Core Viewpoint - The company, Jiao Da Ang Li, has experienced significant fluctuations in its financial performance since its listing 24 years ago, with a notable decline in profitability in recent years [1][3]. Business Overview - Jiao Da Ang Li's main business includes the research, production, and sales of biological products, health foods, and related products, with the highest revenue contribution coming from "other" products at 51.36%, followed closely by health foods at 48.45% [3]. Financial Performance - The company reported a net profit attributable to shareholders of 0.55 billion yuan in its first year of listing in 2001, which decreased to 0.30 billion yuan by the latest complete fiscal year of 2024, marking a cumulative profit decline of 44.22% [3]. - Over the past 24 years, the company has recorded losses in 6 years, with years of profit growth occurring in 15 years, representing 62.5% of the time [3]. - Revenue remained relatively stable, with 3.43 billion yuan in 2020 and 3.25 billion yuan in 2024, although significant fluctuations were noted during this period [3]. - The net profit attributable to shareholders dropped from 0.90 billion yuan in 2020 to 0.30 billion yuan in 2024, indicating a substantial decline in profit levels and stability [3]. Market Capitalization - The peak market capitalization of Jiao Da Ang Li reached 138.31 billion yuan on June 15, 2015, with a corresponding stock price of 44.33 yuan. As of July 1, the market capitalization was 70.75 billion yuan, reflecting a decrease of 67.56 billion yuan, or 48.85% from its peak [5].